Atlas Trials

Validation of a Predictive Model of Response to Romiplostim in Patients With IPSS Low or Intermediate-1 Risk MDS and Thrombocytopenia

Clinical trial NCT02335268 · COMPLETED

Trial details

NCT number
NCT02335268
Sponsor
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Myelodysplastic Syndromes
Start date
2015-05-21
Primary completion
2021-07-01
Enrollment
77

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.